Nintedanib in chronic fibrosing interstitial lung diseases. A case series
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Nintedanib, an antifibrotic drug, shows potential in treating progressive pulmonary fibrosis (PPF) across various causes. This study suggests its effectiveness in patients awaiting lung transplants and the elderly.
Area Of Science
- Pulmonology
- Pharmacology
Background
- Progressive pulmonary fibrosis (PPF) is a fatal condition complicating non-idiopathic interstitial lung diseases.
- Effective therapeutic options for PPF remain limited.
Observation
- A descriptive case series involving 13 patients with PPF treated with nintedanib was conducted.
- Nintedanib is a multitargeted tyrosine kinase inhibitor known for its antifibrotic properties.
Findings
- Results suggest nintedanib may be effective in treating PPF regardless of its underlying etiology.
- The drug's potential benefit was observed in a small cohort, indicating a need for further investigation.
Implications
- Nintedanib could represent a novel therapeutic strategy for managing progressive pulmonary fibrosis.
- The drug may hold particular promise for specific patient groups, including those awaiting lung transplantation and elderly individuals.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.